Background: Although numerous investigators have made efforts to assess prognostic biomarkers of prostate cancer, no biomarker has been recommended for clinical practice.
Methods: According to REMARK and MISFISHIE guidelines, the published literatures of IHC-based prognostic biomarkers on prostate cancer were extracted and pooled.
Results: Ninety-three prognostic biomarkers from 92 high-quality cohort studies were included in this meta-analysis. Our analysis reveals some promising independent prognostic biomarkers, including Ki-67 (ACM HR=1.85, 95% CI=1.06 to 3.25; PSM HR = 1.82, 95% CI = 1.42 to 2.34; DFS HR = 1.51, 95% CI = 1.31 to 1.75); bcl-2 (ACM HR = 2.14, 95% CI = 1.27 to 3.58; PSM HR = 1.61, 95% CI = 1.01 to 2.57; DFS HR = 3.86, 95% CI = 2.14 to 6.96); CD147 (ACM HR=2.63, 95% CI = 1.19 to 5.81; DFS HR = 5.84, 95% CI = 3.41 to 9.99); COX-2 (PSM HR = 7.6, 95% CI = 0.7 to 80.1; DFS HR = 7.9, 95% CI = 2.62 to 23.83); ALDH1A1 (ACM HR = 1.73, 95% CI = 1.163 to 2.527; PSM HR = 1.05, 95% CI = 1.028 to 1.107), and FVIII (ACM HR = 1.76, 95% CI = 1.19 to 2.60; PSM HR = 1.01, 95% CI = 1.01 to 1.02).
Conclusions: Our analysis identified a subset of biomarkers (Ki-67, bcl-2, CD147, COX-2, ALDH1A1, FVIII) that may have prognostic value for predicting the outcome of prostate cancer patients.
Impact: These reliable prognostic biomarkers will improve the clinical management of prostate cancer patients.
Written by:
Zhao L, Yu N, Guo T, Hou Y, Zeng Z, Yang X, Hu P, Tang X, Wang J, Liu M. Are you the author?
Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University.
Reference: Cancer Epidemiol Biomarkers Prev. 2014 Mar 17. Epub ahead of print.
doi: 10.1158/1055-9965.EPI-13-0696
PubMed Abstract
PMID: 24636974
UroToday.com Prostate Cancer Section
